IL17A and systemic lupus erythematosus: On the other hand, UCB-Tregs, as a single agent, have also been shown to resolve SLE inflammation and decrease inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, IL-17A, sCD40L, and IL-1α (22).